Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study

BACKGROUND: Capecitabine plus cisplatin (XP) is recognized as one of the global standard first-line chemotherapy regimens for patients with metastatic gastric cancer (mGC). Recent multinational phase III trials in mGC have been conducted with XP as the control arm, although no data on XP in Japanese...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yamaguchi, Kensei, Sawaki, Akira, Doi, Toshihiko, Satoh, Taroh, Yamada, Yasuhide, Omuro, Yasushi, Nishina, Tomohiro, Boku, Narikazu, Chin, Keisho, Hamamoto, Yasuo, Takiuchi, Hiroya, Komatsu, Yoshito, Saji, Shigehira, Koizumi, Wasaburo, Miyata, Yoshinori, Sato, Atsushi, Baba, Eishi, Tamura, Takao, Abe, Takashi, Ohtsu, Atsushi
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Japan 2012
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3627028/
https://ncbi.nlm.nih.gov/pubmed/22782463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-012-0167-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk